Methadone in Post-Herpetic Neuralgia Pain (NPH)
This study has been completed.
Information provided by (Responsible Party):
Daniel Ciampi Araujo de Andrade, University of Sao Paulo
First received: December 11, 2012
Last updated: March 14, 2013
Last verified: March 2013
Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
||Methadone in Post-Herpetic Neuralgia Pain
Primary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2013 (Final data collection date for primary outcome measure)
in this arm patients will take methadone 5mg.
patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
in this arm patients will take placebo pills.
patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with chronic (>6 months) symptomatic PHN
- with visual analogical scale >40/100mm
- use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)
- Don't full the criteria above
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided by University of Sao Paulo
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
||Daniel Ciampi Araujo de Andrade, MD, PhD, University of Sao Paulo
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 11, 2012
||March 14, 2013
||Brazil: Ethics Committee
Keywords provided by University of Sao Paulo:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 22, 2014
Nervous System Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents
Sensory System Agents